InvestorsHub Logo
Followers 0
Posts 2865
Boards Moderated 0
Alias Born 10/31/2006

Re: Lakers_w post# 39947

Saturday, 02/19/2022 10:48:56 AM

Saturday, February 19, 2022 10:48:56 AM

Post# of 40503
From the article - monkeys. The results look to be preclinical and I have never seen an official % efficacy released from Inovio (the official source of info) for any phase of testing.
…….,
“INO-4800 is a plasmid DNA vaccine developed by Inovio Pharmaceuticals (USA) for preclinical testing within the ferret model of COVID-19. This DNA vaccine encoding the S protein was delivered by electroporation [33]. INO-4800 was able to reduce viral load in non-human primates; rhesus macaque, used as model, that received two doses (1 mg) for 4 weeks of the DNA vaccine showed humoral and cellular immune responses after 13 weeks [38]. The vaccine s+howed effectiveness against both D614 and G614 SARS-CoV-2 variants [38]. The study of safety, tolerability, and immunogenicity of INO-4800 for COVID-19 was tested in healthy volunteers using SARS-CoV-2 spike glycoprotein as antigen”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INO News